| Citation: |
QIU Xiao-dan, ZHANG Yi, BAI Yu. Study on the Mechanism of Tamoxifen against Breast Cancer by Mass Spectrometry Based Single-Cell Metabolomics[J]. Journal of Chinese Mass Spectrometry Society, 2024, 45(6): 785-792. DOI: 10.7538/zpxb.2024.0169
|
Breast cancer is a malignant tumor that predominantly affects women. The incidence of breast cancer has risen annually and is increasingly occurring in younger population, posing a significant threat to women’s health. Estrogen receptor-positive breast cancer is the most prevalent subtype, accounting for 75% of all cases. Endocrine therapy, particularly with tamoxifen, serves as the primary treatment for these subtypes. However, due to the highly heterogeneous nature of breast cancer, some patients remain at risk for recurrence even after undergoing tamoxifen treatment. Therefore, it is essential to investigate the mechanism of tamoxifen in breast cancer treatment from a single-cell perspective. In comparison to single-cell genomics and single-cell proteomics, single-cell metabolomics can offer a clearer representation of the chemical changes occurring within individual cells by measuring the end products of cellular activity—metabolites. Thus, this approach can provide a more direct reflection of the differences between cells. In this study, single-cell mass cytometry was employed to investigate metabolite alterations in MCF-7 cells upon exposure to tamoxifen, aiming to elucidate its mechanism from a single-cell perspective. The 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay was utilized to assess the impact of tamoxifen on MCF-7 cell proliferation and established optimal conditions for subsequent therapies involving these cells. The results showed that 576 metabolites under positive ion mode and 480 metabolites under negative ion mode are identified by using single-cell mass cytometry approach. In total, 811 metabolites are detected in MCF-7 cells without tamoxifen treatment compared to 776 metabolites identified following tamoxifen administration. It demonstrated that metabolites observed under negative ion mode effectively distinguish between MCF-7 cells treated with and without tamoxifen. Exposure to tamoxifen can result in upregulation of 28 metabolites and downregulation of 59 metabolites, and these changes predominantly influence metabolic pathways including taurine-hypotaurine metabolism, caffeine metabolism, cysteine-methionine metabolism, glycine-serine-threonine metabolism, purine metabolism, starch-sucrose metabolism, and pyrimidine metabolism. The findings indicated that the intervention of the aforementioned metabolites and metabolic pathways may represent one of the mechanisms through which tamoxifen exerts its effects against estrogen receptor-positive breast cancer. This study employed single-cell metabolomics based on mass spectrometry to explore the metabolic alterations in breast cancer cells induced by tamoxifen, which is often overlooked in metabolomics studies based on bulk cells. Furthermore, it elucidates the mechanism of tamoxifen’s action against estrogen receptor-positive breast cancer from a single-cell metabolomic perspective, thereby provides valuable insights for understanding the mechanisms underlying other therapeutic agents.
| [1] |
HARBECK N, PENAULT-LLORCA F, CORTES J, GNANT M, HOUSSAMI N, POORTMANS P, RUDDY K, TSANG J, CARDOSO F. Breast cancer[J]. Nature Reviews Disease Primers, 2019, 5(1):
|
| [2] |
YANOVICH G, AGMON H, HAREL M, SONNENBLICK A, PERETZ T, GEIGER T. Clinical proteomics of breast cancer reveals a novel layer of breast cancer classification[J]. Cancer Research, 2018, 78(20): 6 001-6 010.
|
| [3] |
YU T J, MA D, LIU Y Y, XIAO Y, GONG Y, JIANG Y Z, SHAO Z M, HU X, DI G H. Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers[J]. Molecular Therapy, 2021, 29(7): 2 350-2 365.
|
| [4] |
WAKS A G, WINER E P. Breast cancer treatment[J]. The Journal of the American Medical Association, 2019, 321(3):
|
| [5] |
GUO L, KONG D, LIU J, ZHAN L, LUO L, ZHENG W, ZHENG Q, CHEN C, SUN S. Breast cancer heterogeneity and its implication in personalized precision therapy[J]. Experimental Hematology & Oncology, 2023, 12(1):
|
| [6] |
LIU S, GAO Z, WU J, ZHENG H, LI B, SUN S, MENG X, WU Q. Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer[J]. Journal of Hematology & Oncology, 2022, 15(1):
|
| [7] |
FESSENDEN M. Metabolomics: small molecules, single cells[J]. Nature, 2016, 540(7 631): 153-155.
|
| [8] |
SEYDEL C. Single-cell metabolomics hits its stride[J]. Nature Methods, 2021, 18(12): 1 452-1 456.
|
| [9] |
CHENG H, TANG Y, LI Z, GUO Z, HEATH J R, XUE M, WEI W. Non-mass spectrometric targeted single-cell metabolomics[J]. TrAC Trends in Analytical Chemistry, 2023, 168: 117 300.
|
| [10] |
QIN S, MIAO D, ZHANG X, ZHANG Y, BAI Y. Methods developments of mass spectrometry based single cell metabolomics[J]. TrAC Trends in Analytical Chemistry, 2023, 164: 117 086.
|
| [11] |
XU T, LI H, DOU P, LUO Y, PU S, MU H, ZHANG Z, FENG D, HU X, WANG T, TAN G, CHEN C, LI H, SHI X, HU C, XU G. Concentric hybrid nanoelectrospray ionization-atmospheric pressure chemical ionization source for high-coverage mass spectrometry analysis of single-cell metabolomics[J]. Advanced Science, 2024, 11(16): 2 306 659.
|
| [12] |
HU R, LI Y, YANG Y, LIU M. Mass spectrometry-based strategies for single-cell metabolomics[J]. Mass Spectrometry Reviews, 2023, 42(1):
|
| [13] |
YU X, HE M, CHEN B, HU B. Recent advances in single-cell analysis by inductively coupled plasma-mass spectrometry: a review[J]. Analytica Chimica Acta, 2020, 1 137(15): 191-207.
|
| [14] |
PAPAGIANNOPOULOU C, PARCHEN R, RUBBENS P, WAEGEMAN W. Fast pathogen identification using single-cell matrix-assisted laser desorption/ionization-aerosol time-of-flight mass spectrometry data and deep learning methods[J]. Analytical Chemistry, 2020, 92(11): 7 523-7 531.
|
| [15] |
SWEEDLER J V. Single cell profiling using ionic liquid matrix-enhanced secondary ion mass spectrometry for neuronal cell type differentiation[J]. Analytical Chemistry, 2017, 89(5): 3 078-3 086.
|
| [16] |
XU T, FENG D, LI H, HU X, WANG T, HU C, SHI X, XU G. Recent advances and typical applications in mass spectrometry-based technologies for single-cell metabolite analysis[J]. TrAC Trends in Analytical Chemistry, 2022, 157: 116 763.
|
| [17] |
YAO H, ZHAO H, ZHAO X, PAN X, FENG J, XU F, ZHANG S, ZHANG X. Label-free mass cytometry for unveiling cellular metabolic heterogeneity[J]. Analytical Chemistry, 2019, 91(15): 9 777-9 783.
|
| [18] |
FUJII T, MATSUDA S, TEJEDOR M L, ESAKI T, SAKANE I, MIZUNO H, TSUYAMA N, MASUJIMA T. Direct metabolomics for plant cells by live single-cell mass spectrometry[J]. Nature Protocols, 2015, 10(9): 1 445-1 456.
|
| [19] |
STANDKE S J, COLBY D H, BENSEN R C, BURGETT A W G, YANG Z. Mass spectrometry measurement of single suspended cells using a combined cell manipulation system and a single-probe device[J]. Analytical Chemistry, 2019, 91(3): 1 738-1 742.
|
| [20] |
SHAO Y, ZHOU Y, LIU Y, ZHANG W, ZHU G, ZHAO Y, ZHANG Q, YAO H, ZHAO H, GUO G, ZHANG S, ZHANG X, WANG X. Intact living-cell electrolaunching ionization mass spectrometry for single-cell metabolomics[J]. Chemical Science, 2022, 13(27): 8 065-8 073.
|
| [21] |
ZHU G, ZHANG W, ZHAO Y, CHEN T, YUAN H, LIU Y, GUO G, LIU Z, WANG X. Single-cell metabolomics-based strategy for studying the mechanisms of drug action[J]. Analytical Chemistry, 2023, 95(10): 4 712-4 720.
|
| [22] |
XU S, LIU M, BAI Y, LIU H. Multi-dimensional organic mass cytometry: simultaneous analysis of proteins and metabolites on single cells[J]. Angewandte Chemie International Edition, 2021, 60(4): 1 806-1 812.
|
| [23] |
QIN S, ZHANG Y, SHI M, MIAO D, LU J, WEN L, BAI Y. In-depth organic mass cytometry reveals differential contents of 3-hydroxybutanoic acid at the single-cell level[J]. Nature Communications, 2024, 15: 4 387.
|
| [24] |
QIU H, SHAO N, LIU J, ZHAO J, CHEN C, LI Q, HE Z, ZHAO X, XU L. Amino acid metabolism in tumor: new shine in the fog?[J]. Clinical Nutrition, 2023, 42(8): 1 521-1 530.
|
| [25] |
XU Q, LI Y, GAO X, KANG K, WILLIAMS J G, TONG L, LIU J, JI M, DETERDING L J, TONG X, LOCASALE J W, LI L, SHATS I, LI X. HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer[J]. Nature Communications, 2020, 11: 3 978.
|
| [26] |
SHI D D, SAVANI M R, ABDULLAH K G, McBRAYER S K. Emerging roles of nucleotide metabolism in cancer[J]. Trends in Cancer, 2023, 9(8):
|
| [27] |
MULLEN N J, SINGH P K. Nucleotide metabolism: a pan-cancer metabolic dependency[J]. Nature Reviews Cancer, 2023, 23(5):
|
| [28] |
MADSEN H B, PEETERS M J, thor STRATEN P, DESLER C. Nucleotide metabolism in the regulation of tumor microenvironment and immune cell function[J]. Current Opinion in Biotechnology, 2023, 84: 103 008.
|
| [29] |
TRAN D H, KIM D, KESAVAN R, BROWN H, DEY T, SOFLAEE M H, VU H S, TASDOGAN A, GUO J, BEZWADA D, AL SAAD H, CAI F, SOLMONSON A, RION H, CHABATYA R, MERCHANT S, MANALES N J, TCHEUYAP V T, MULKEY M, MATHEWS T P, BRUGAROLAS J, MORRISON S J, ZHU H, DeBERARDINIS R J, HOXHAJ G. De novo and salvage purine synthesis pathways across tissues and tumors[J]. Cell, 2024, 187(14): 3 602-3 618.
|
| [30] |
FU Y, WEI X D, GUO L, WU K, LE J, MA Y, KONG X, TONG Y, WU H. The metabolic and non-metabolic roles of UCK2 in tumor progression[J]. Frontiers in Oncology, 2022, 12: 904 887.
|
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: